Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Gianluca Gaïdano, Francesco Forconi et al.|Blood|2015Cited by 215
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Gianluca Gaïdano, Riccardo Moia et al.|Haematologica|2019Cited by 87
Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemiaRiccardo Moia, Gianluca Gaïdano, Riccardo Dondolin et al.|Hematological Oncology|2022Cited by 4
Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR TreatmentRiccardo Moia, Davide Rossi, Fary Diop et al.|Clinical Lymphoma Myeloma & Leukemia|2017Cited by 1
<i>CAT</i> rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic LeukemiaMarilisa Galasso, Maria Teresa Scupoli, Vittoria Salaorni et al.|Hematological Oncology|2024Cited by 1